Wellous Pharma Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
- Paid Up Capital ₹ 5.90 Cr
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.07 Cr
- Revenue Growth 7.79%
- Profit Growth 1600.19%
- Ebitda 33.30%
- Net Worth 7.45%
- Total Assets -19.56%
About Wellous Pharma
Wellous Pharma Private Limited (WPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 04 October 2016 (Eight years and three months 27 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.90 Cr.
The company currently has active open charges totaling ₹7.07 Cr.
Karunakaran, Venkatesan Govindan, and Bharat Doss serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24304TN2016PTC112803
- Company No.
112803
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Wellous Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karunakaran  | Director | 04-Oct-2016 | Current |
| Venkatesan Govindan | Director | 04-Oct-2016 | Current |
| Bharat Doss | Director | 10-Oct-2022 | Current |
Financial Performance of Wellous Pharma.
Wellous Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.79% increase. The company also saw a substantial improvement in profitability, with a 1600.19% increase in profit. The company's net worth moved up by a moderate rise of 7.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wellous Pharma?
In 2023, Wellous Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.07 Cr
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 7.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Nov 2017 | Indian Bank | ₹7.07 Cr | Open |
How Many Employees Work at Wellous Pharma?
Wellous Pharma has a workforce of 75 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wellous Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wellous Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.